世界のPEG化タンパク質治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global PEGylated Protein Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4491 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、PEG化タンパク質治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（コロニー刺激因子、インターフェロン、エリスロポエチン（EPO）、組換え第VIII因子、モノクローナル抗体、酵素、その他）、用途別市場規模（がん、自己免疫疾患、肝炎、多発性硬化症、血友病、胃腸障害、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・PEG化タンパク質治療薬の市場動向 ・企業の競争状況、市場シェア ・PEG化タンパク質治療薬の種類別市場規模（コロニー刺激因子、インターフェロン、エリスロポエチン（EPO）、組換え第VIII因子、モノクローナル抗体、酵素、その他） ・PEG化タンパク質治療薬の用途別市場規模（がん、自己免疫疾患、肝炎、多発性硬化症、血友病、胃腸障害、その他） ・PEG化タンパク質治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・PEG化タンパク質治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・PEG化タンパク質治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・PEG化タンパク質治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・PEG化タンパク質治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Merck、Pfizer、UCB、Amgen、AstraZeneca、Biogen、Roche、Horizon Pharma、Leadiant Biosciences） ・結論

PEGylation is the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to molecules, such as a drug, therapeutic protein, or vesicle. PEGylated protein therapeutics is estimated to show significant market growth during the forecast period, majorly due to the, growth in demand for PEGylation, rise in number of chronic diseases, and presence of strong pipeline drugs.
Higher process cost associated with PEGylation and patent expiry of certain drugs are projected to hinder the market growth.

Market Analysis and Insights: Global PEGylated Protein Therapeutics Market
The global PEGylated Protein Therapeutics market size is projected to reach US$ 12770 million by 2026, from US$ 9730.2 million in 2019, at a CAGR of 3.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global PEGylated Protein Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global PEGylated Protein Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global PEGylated Protein Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global PEGylated Protein Therapeutics market.

Global PEGylated Protein Therapeutics Scope and Market Size
PEGylated Protein Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global PEGylated Protein Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Colony Stimulating Factor
Interferon
Erythropoietin (EPO)
Recombinant Factor VIII
Monoclonal Antibody
Enzyme
Others

Segment by Application
Cancer
Autoimmune Disease
Hepatitis
Multiple Sclerosis
Hemophilia
Gastrointestinal Disorder
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Merck
Pfizer
UCB
Amgen
AstraZeneca
Biogen
Roche
Horizon Pharma
Leadiant Biosciences

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PEGylated Protein Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Colony Stimulating Factor
1.2.3 Interferon
1.2.4 Erythropoietin (EPO)
1.2.5 Recombinant Factor VIII
1.2.6 Monoclonal Antibody
1.2.7 Enzyme
1.2.8 Others
1.3 Market by Application
1.3.1 Global PEGylated Protein Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Cancer
1.3.3 Autoimmune Disease
1.3.4 Hepatitis
1.3.5 Multiple Sclerosis
1.3.6 Hemophilia
1.3.7 Gastrointestinal Disorder
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global PEGylated Protein Therapeutics Market Perspective (2016-2027)
2.2 PEGylated Protein Therapeutics Growth Trends by Regions
2.2.1 PEGylated Protein Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 PEGylated Protein Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 PEGylated Protein Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 PEGylated Protein Therapeutics Industry Dynamic
2.3.1 PEGylated Protein Therapeutics Market Trends
2.3.2 PEGylated Protein Therapeutics Market Drivers
2.3.3 PEGylated Protein Therapeutics Market Challenges
2.3.4 PEGylated Protein Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top PEGylated Protein Therapeutics Players by Revenue
3.1.1 Global Top PEGylated Protein Therapeutics Players by Revenue (2016-2021)
3.1.2 Global PEGylated Protein Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global PEGylated Protein Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by PEGylated Protein Therapeutics Revenue
3.4 Global PEGylated Protein Therapeutics Market Concentration Ratio
3.4.1 Global PEGylated Protein Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PEGylated Protein Therapeutics Revenue in 2020
3.5 PEGylated Protein Therapeutics Key Players Head office and Area Served
3.6 Key Players PEGylated Protein Therapeutics Product Solution and Service
3.7 Date of Enter into PEGylated Protein Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 PEGylated Protein Therapeutics Breakdown Data by Type
4.1 Global PEGylated Protein Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global PEGylated Protein Therapeutics Forecasted Market Size by Type (2022-2027)

5 PEGylated Protein Therapeutics Breakdown Data by Application
5.1 Global PEGylated Protein Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global PEGylated Protein Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America PEGylated Protein Therapeutics Market Size (2016-2027)
6.2 North America PEGylated Protein Therapeutics Market Size by Type
6.2.1 North America PEGylated Protein Therapeutics Market Size by Type (2016-2021)
6.2.2 North America PEGylated Protein Therapeutics Market Size by Type (2022-2027)
6.2.3 North America PEGylated Protein Therapeutics Market Size by Type (2016-2027)
6.3 North America PEGylated Protein Therapeutics Market Size by Application
6.3.1 North America PEGylated Protein Therapeutics Market Size by Application (2016-2021)
6.3.2 North America PEGylated Protein Therapeutics Market Size by Application (2022-2027)
6.3.3 North America PEGylated Protein Therapeutics Market Size by Application (2016-2027)
6.4 North America PEGylated Protein Therapeutics Market Size by Country
6.4.1 North America PEGylated Protein Therapeutics Market Size by Country (2016-2021)
6.4.2 North America PEGylated Protein Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe PEGylated Protein Therapeutics Market Size (2016-2027)
7.2 Europe PEGylated Protein Therapeutics Market Size by Type
7.2.1 Europe PEGylated Protein Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe PEGylated Protein Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe PEGylated Protein Therapeutics Market Size by Type (2016-2027)
7.3 Europe PEGylated Protein Therapeutics Market Size by Application
7.3.1 Europe PEGylated Protein Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe PEGylated Protein Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe PEGylated Protein Therapeutics Market Size by Application (2016-2027)
7.4 Europe PEGylated Protein Therapeutics Market Size by Country
7.4.1 Europe PEGylated Protein Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe PEGylated Protein Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific PEGylated Protein Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific PEGylated Protein Therapeutics Market Size by Type
8.2.1 Asia-Pacific PEGylated Protein Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific PEGylated Protein Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific PEGylated Protein Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific PEGylated Protein Therapeutics Market Size by Application
8.3.1 Asia-Pacific PEGylated Protein Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific PEGylated Protein Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific PEGylated Protein Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific PEGylated Protein Therapeutics Market Size by Region
8.4.1 Asia-Pacific PEGylated Protein Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific PEGylated Protein Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America PEGylated Protein Therapeutics Market Size (2016-2027)
9.2 Latin America PEGylated Protein Therapeutics Market Size by Type
9.2.1 Latin America PEGylated Protein Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America PEGylated Protein Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America PEGylated Protein Therapeutics Market Size by Type (2016-2027)
9.3 Latin America PEGylated Protein Therapeutics Market Size by Application
9.3.1 Latin America PEGylated Protein Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America PEGylated Protein Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America PEGylated Protein Therapeutics Market Size by Application (2016-2027)
9.4 Latin America PEGylated Protein Therapeutics Market Size by Country
9.4.1 Latin America PEGylated Protein Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America PEGylated Protein Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa PEGylated Protein Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa PEGylated Protein Therapeutics Market Size by Type
10.2.1 Middle East & Africa PEGylated Protein Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa PEGylated Protein Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa PEGylated Protein Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa PEGylated Protein Therapeutics Market Size by Application
10.3.1 Middle East & Africa PEGylated Protein Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa PEGylated Protein Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa PEGylated Protein Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa PEGylated Protein Therapeutics Market Size by Country
10.4.1 Middle East & Africa PEGylated Protein Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa PEGylated Protein Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck PEGylated Protein Therapeutics Introduction
11.1.4 Merck Revenue in PEGylated Protein Therapeutics Business (2016-2021)
11.1.5 Merck Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer PEGylated Protein Therapeutics Introduction
11.2.4 Pfizer Revenue in PEGylated Protein Therapeutics Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 UCB
11.3.1 UCB Company Details
11.3.2 UCB Business Overview
11.3.3 UCB PEGylated Protein Therapeutics Introduction
11.3.4 UCB Revenue in PEGylated Protein Therapeutics Business (2016-2021)
11.3.5 UCB Recent Development
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen PEGylated Protein Therapeutics Introduction
11.4.4 Amgen Revenue in PEGylated Protein Therapeutics Business (2016-2021)
11.4.5 Amgen Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca PEGylated Protein Therapeutics Introduction
11.5.4 AstraZeneca Revenue in PEGylated Protein Therapeutics Business (2016-2021)
11.5.5 AstraZeneca Recent Development
11.6 Biogen
11.6.1 Biogen Company Details
11.6.2 Biogen Business Overview
11.6.3 Biogen PEGylated Protein Therapeutics Introduction
11.6.4 Biogen Revenue in PEGylated Protein Therapeutics Business (2016-2021)
11.6.5 Biogen Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche PEGylated Protein Therapeutics Introduction
11.7.4 Roche Revenue in PEGylated Protein Therapeutics Business (2016-2021)
11.7.5 Roche Recent Development
11.8 Horizon Pharma
11.8.1 Horizon Pharma Company Details
11.8.2 Horizon Pharma Business Overview
11.8.3 Horizon Pharma PEGylated Protein Therapeutics Introduction
11.8.4 Horizon Pharma Revenue in PEGylated Protein Therapeutics Business (2016-2021)
11.8.5 Horizon Pharma Recent Development
11.9 Leadiant Biosciences
11.9.1 Leadiant Biosciences Company Details
11.9.2 Leadiant Biosciences Business Overview
11.9.3 Leadiant Biosciences PEGylated Protein Therapeutics Introduction
11.9.4 Leadiant Biosciences Revenue in PEGylated Protein Therapeutics Business (2016-2021)
11.9.5 Leadiant Biosciences Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global PEGylated Protein Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Colony Stimulating Factor
Table 3. Key Players of Interferon
Table 4. Key Players of Erythropoietin (EPO)
Table 5. Key Players of Recombinant Factor VIII
Table 6. Key Players of Monoclonal Antibody
Table 7. Key Players of Enzyme
Table 8. Key Players of Others
Table 9. Global PEGylated Protein Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global PEGylated Protein Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global PEGylated Protein Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global PEGylated Protein Therapeutics Market Share by Regions (2016-2021)
Table 13. Global PEGylated Protein Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global PEGylated Protein Therapeutics Market Share by Regions (2022-2027)
Table 15. PEGylated Protein Therapeutics Market Trends
Table 16. PEGylated Protein Therapeutics Market Drivers
Table 17. PEGylated Protein Therapeutics Market Challenges
Table 18. PEGylated Protein Therapeutics Market Restraints
Table 19. Global PEGylated Protein Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global PEGylated Protein Therapeutics Market Share by Players (2016-2021)
Table 21. Global Top PEGylated Protein Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PEGylated Protein Therapeutics as of 2020)
Table 22. Ranking of Global Top PEGylated Protein Therapeutics Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by PEGylated Protein Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players PEGylated Protein Therapeutics Product Solution and Service
Table 26. Date of Enter into PEGylated Protein Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global PEGylated Protein Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 29. Global PEGylated Protein Therapeutics Revenue Market Share by Type (2016-2021)
Table 30. Global PEGylated Protein Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global PEGylated Protein Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global PEGylated Protein Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global PEGylated Protein Therapeutics Revenue Market Share by Application (2016-2021)
Table 34. Global PEGylated Protein Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global PEGylated Protein Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America PEGylated Protein Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 37. North America PEGylated Protein Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America PEGylated Protein Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 39. North America PEGylated Protein Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America PEGylated Protein Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America PEGylated Protein Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe PEGylated Protein Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe PEGylated Protein Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe PEGylated Protein Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe PEGylated Protein Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe PEGylated Protein Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe PEGylated Protein Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific PEGylated Protein Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific PEGylated Protein Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific PEGylated Protein Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific PEGylated Protein Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific PEGylated Protein Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific PEGylated Protein Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America PEGylated Protein Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America PEGylated Protein Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America PEGylated Protein Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America PEGylated Protein Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America PEGylated Protein Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America PEGylated Protein Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa PEGylated Protein Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa PEGylated Protein Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa PEGylated Protein Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa PEGylated Protein Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa PEGylated Protein Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa PEGylated Protein Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 66. Merck Company Details
Table 67. Merck Business Overview
Table 68. Merck PEGylated Protein Therapeutics Product
Table 69. Merck Revenue in PEGylated Protein Therapeutics Business (2016-2021) & (US$ Million)
Table 70. Merck Recent Development
Table 71. Pfizer Company Details
Table 72. Pfizer Business Overview
Table 73. Pfizer PEGylated Protein Therapeutics Product
Table 74. Pfizer Revenue in PEGylated Protein Therapeutics Business (2016-2021) & (US$ Million)
Table 75. Pfizer Recent Development
Table 76. UCB Company Details
Table 77. UCB Business Overview
Table 78. UCB PEGylated Protein Therapeutics Product
Table 79. UCB Revenue in PEGylated Protein Therapeutics Business (2016-2021) & (US$ Million)
Table 80. UCB Recent Development
Table 81. Amgen Company Details
Table 82. Amgen Business Overview
Table 83. Amgen PEGylated Protein Therapeutics Product
Table 84. Amgen Revenue in PEGylated Protein Therapeutics Business (2016-2021) & (US$ Million)
Table 85. Amgen Recent Development
Table 86. AstraZeneca Company Details
Table 87. AstraZeneca Business Overview
Table 88. AstraZeneca PEGylated Protein Therapeutics Product
Table 89. AstraZeneca Revenue in PEGylated Protein Therapeutics Business (2016-2021) & (US$ Million)
Table 90. AstraZeneca Recent Development
Table 91. Biogen Company Details
Table 92. Biogen Business Overview
Table 93. Biogen PEGylated Protein Therapeutics Product
Table 94. Biogen Revenue in PEGylated Protein Therapeutics Business (2016-2021) & (US$ Million)
Table 95. Biogen Recent Development
Table 96. Roche Company Details
Table 97. Roche Business Overview
Table 98. Roche PEGylated Protein Therapeutics Product
Table 99. Roche Revenue in PEGylated Protein Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Roche Recent Development
Table 101. Horizon Pharma Company Details
Table 102. Horizon Pharma Business Overview
Table 103. Horizon Pharma Revenue in PEGylated Protein Therapeutics Business (2016-2021) & (US$ Million)
Table 104. Horizon Pharma Recent Development
Table 105. Leadiant Biosciences Company Details
Table 106. Leadiant Biosciences Business Overview
Table 107. Leadiant Biosciences PEGylated Protein Therapeutics Product
Table 108. Leadiant Biosciences Revenue in PEGylated Protein Therapeutics Business (2016-2021) & (US$ Million)
Table 109. Leadiant Biosciences Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global PEGylated Protein Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Colony Stimulating Factor Features
Figure 3. Interferon Features
Figure 4. Erythropoietin (EPO) Features
Figure 5. Recombinant Factor VIII Features
Figure 6. Monoclonal Antibody Features
Figure 7. Enzyme Features
Figure 8. Others Features
Figure 9. Global PEGylated Protein Therapeutics Market Share by Application: 2020 VS 2027
Figure 10. Cancer Case Studies
Figure 11. Autoimmune Disease Case Studies
Figure 12. Hepatitis Case Studies
Figure 13. Multiple Sclerosis Case Studies
Figure 14. Hemophilia Case Studies
Figure 15. Gastrointestinal Disorder Case Studies
Figure 16. Others Case Studies
Figure 17. PEGylated Protein Therapeutics Report Years Considered
Figure 18. Global PEGylated Protein Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 19. Global PEGylated Protein Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 20. Global PEGylated Protein Therapeutics Market Share by Regions: 2020 VS 2027
Figure 21. Global PEGylated Protein Therapeutics Market Share by Regions (2022-2027)
Figure 22. Global PEGylated Protein Therapeutics Market Share by Players in 2020
Figure 23. Global Top PEGylated Protein Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PEGylated Protein Therapeutics as of 2020
Figure 24. The Top 10 and 5 Players Market Share by PEGylated Protein Therapeutics Revenue in 2020
Figure 25. Global PEGylated Protein Therapeutics Revenue Market Share by Type (2016-2021)
Figure 26. Global PEGylated Protein Therapeutics Revenue Market Share by Type (2022-2027)
Figure 27. North America PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. North America PEGylated Protein Therapeutics Market Share by Type (2016-2027)
Figure 29. North America PEGylated Protein Therapeutics Market Share by Application (2016-2027)
Figure 30. North America PEGylated Protein Therapeutics Market Share by Country (2016-2027)
Figure 31. United States PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Canada PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Europe PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Europe PEGylated Protein Therapeutics Market Share by Type (2016-2027)
Figure 35. Europe PEGylated Protein Therapeutics Market Share by Application (2016-2027)
Figure 36. Europe PEGylated Protein Therapeutics Market Share by Country (2016-2027)
Figure 37. Germany PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. France PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. U.K. PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Italy PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Russia PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Nordic PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Asia-Pacific PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Asia-Pacific PEGylated Protein Therapeutics Market Share by Type (2016-2027)
Figure 45. Asia-Pacific PEGylated Protein Therapeutics Market Share by Application (2016-2027)
Figure 46. Asia-Pacific PEGylated Protein Therapeutics Market Share by Region (2016-2027)
Figure 47. China PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Japan PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. South Korea PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Southeast Asia PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. India PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Australia PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Latin America PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Latin America PEGylated Protein Therapeutics Market Share by Type (2016-2027)
Figure 55. Latin America PEGylated Protein Therapeutics Market Share by Application (2016-2027)
Figure 56. Latin America PEGylated Protein Therapeutics Market Share by Country (2016-2027)
Figure 57. Mexico PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Brazil PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Middle East & Africa PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Middle East & Africa PEGylated Protein Therapeutics Market Share by Type (2016-2027)
Figure 61. Middle East & Africa PEGylated Protein Therapeutics Market Share by Application (2016-2027)
Figure 62. Middle East & Africa PEGylated Protein Therapeutics Market Share by Country (2016-2027)
Figure 63. Turkey PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 64. Saudi Arabia PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 65. UAE PEGylated Protein Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 66. Merck Revenue Growth Rate in PEGylated Protein Therapeutics Business (2016-2021)
Figure 67. Pfizer Revenue Growth Rate in PEGylated Protein Therapeutics Business (2016-2021)
Figure 68. UCB Revenue Growth Rate in PEGylated Protein Therapeutics Business (2016-2021)
Figure 69. Amgen Revenue Growth Rate in PEGylated Protein Therapeutics Business (2016-2021)
Figure 70. AstraZeneca Revenue Growth Rate in PEGylated Protein Therapeutics Business (2016-2021)
Figure 71. Biogen Revenue Growth Rate in PEGylated Protein Therapeutics Business (2016-2021)
Figure 72. Roche Revenue Growth Rate in PEGylated Protein Therapeutics Business (2016-2021)
Figure 73. Horizon Pharma Revenue Growth Rate in PEGylated Protein Therapeutics Business (2016-2021)
Figure 74. Leadiant Biosciences Revenue Growth Rate in PEGylated Protein Therapeutics Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed

---